B2M and melanoma: In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD-1, β2M LOH was enriched threefold in non-responders (~ 30%) compared to responders (~ 10%), and loss of both copies of β2M was found only in non-responders [23].